Core Viewpoint - The company Yili Group confirms that its milk powder products containing ARA (Arachidonic Acid) are safe and that production operations are normal, amidst a global recall by Nestlé due to contamination concerns [1] Group 1 - Nestlé has initiated a "preventive voluntary recall" of certain batches of infant formula in 31 countries and regions due to the detection of trace amounts of Cereulide (a toxin produced by Bacillus cereus) in ARA oil supplied by one of its suppliers [1] - One of Nestlé's ARA suppliers, Jabiou, is currently conducting an investigation into the contamination issue [1]

Core Viewpoint - The company has issued a statement regarding the safety and supply chain of ARA (Arachidonic Acid) in response to a preventive recall in the European market due to potential contamination by Cereulid toxin [1] Group 1: Supplier Verification - The company confirmed that all products containing ARA are sourced from suppliers that are not involved in the European recall incident [1] - The ARA suppliers have undergone rigorous safety certification processes [1] Group 2: Testing Standards - The company emphasizes strict testing standards for microbial risks, particularly focusing on Bacillus cereus and its toxins [1] - Each batch of finished products has passed multiple sensory, physical, chemical, and microbiological tests conducted by third-party authoritative testing agencies, including tests for pathogenic bacteria [1]

Core Insights - The article highlights the transformation of Jia Bi You Biotechnology (Wuhan) Co., Ltd. from a single nutrient supplier to a synthetic biology platform enterprise over six years since its listing on the Sci-Tech Innovation Board, marking a significant milestone in China's food biotechnology sector [1] Financial Performance - Jia Bi You's revenue has grown from 312 million yuan in 2019 to 555 million yuan in 2024, achieving a compound annual growth rate (CAGR) of 12.2% [2] - In 2025, the company reported a revenue of 428 million yuan and a net profit of 129 million yuan in the first three quarters, reflecting a year-on-year increase of 54.18%, surpassing the total net profit for 2024 [2] - As of December 19, 2025, the company's market capitalization exceeded 3.9 billion yuan, demonstrating significant growth since its initial public offering [2] Product Development and Market Position - The company has expanded its product matrix, achieving over 40% global market share in ARA (Arachidonic Acid) and surpassing 100 million yuan in annual sales for DHA (Docosahexaenoic Acid) [2] - Jia Bi You has developed a diverse product system covering human nutrition, animal nutrition, and personal care, with 114 authorized products for SA (Sialic Acid) [2] - The successful mass production of 2'-fucosyllactose (2'-FL) in 2025 fills a significant gap in China's HMO (Human Milk Oligosaccharides) market [2] Supply Chain and Risk Management - The company has established a fully controllable supply chain, achieving domestic substitution across the entire production process from strain cultivation to fermentation and product application [3] - The second phase of the Wuhan production base has positioned the company among the global leaders in ARA and DHA production capacity [3] - Jia Bi You's products have received international certifications and are exported to over 30 countries, establishing stable partnerships with global giants like Nestlé [3] Research and Development - Jia Bi You maintains a research and development investment of over 8%, with 2024 R&D expenditure reaching 47.9 million yuan, a 24.12% increase year-on-year [4] - The company has developed a full-stack technology loop integrating AI and synthetic biology, breaking foreign monopolies in industrial strains [4] - The establishment of a national pilot platform for microbial fermentation supports the transition from laboratory to production line [4] Industry Standards and Future Strategy - Jia Bi You has actively participated in the formulation of national food safety standards and was selected for the national synthetic biology standardization project research group in 2025 [5] - The company aims to focus on high-end equipment development and advanced molecular layout, targeting the trillion-yuan market outlined in the 14th Five-Year Plan [5] - Future plans include upgrading the pilot platform to a public service hub for bio-manufacturing and deepening global cooperation to expand into European, American, and Southeast Asian markets [5]